Endodontics Market worth 1.61 Billion USD by 2022

The report "Endodontics Market by Instruments (Scalers, Apex Locator, Motors, Handpiece, Laser), Consumables (Access Cavity Preparation, Endodontic Files, Burs, Drill, Lubricant, Obturation), End User (Clinic, Hospital) - Global Forecast to 2022", The global endodontics market is projected to reach USD 1.61 Billion by 2022 from USD 1.26 Billion in 2017, at a CAGR of 5.1% during the forecast period. Growth in this market is attributed to the rapid growth in the geriatric population, increasing number of dentists and dental practices, rising dental tourism, increasing dental expenditure, and an increase in disposable incomes.

Browse 194 Market Data Tables and 27 Figures spread through 193 Pages and in-depth TOC on "Endodontics Market by Instruments (Scalers, Apex Locator, Motors, Handpiece, Laser), Consumables (Access Cavity Preparation, Endodontic Files, Burs, Drill, Lubricant, Obturation), End User (Clinic, Hospital) - Global Forecast to 2022"
https://www.marketsandmarkets.com/Market-Reports/endodontics-market-222473576.html
Early buyers will receive 10% customization on reports.

The consumables segment to dominate the endodontics market during the forecast period

Based on product, the endodontics market is segmented into consumables and instruments. The consumables segment accounted for the major share of the global endodontics market and is also expected to register the highest CAGR during the forecast period. The large share and high growth of this segment can primarily be attributed to the growing number of root canal procedures globally.

Dental clinics to witness the highest growth rate during the forecast period

On the basis of end users, the endodontics market is segmented into dental clinics, dental hospitals, and dental academic & research institutes. The dental clinics segment accounted for the major share of the global endodontics market and is also expected to register the highest CAGR during the forecast period. The large share of this end-user segment is attributed to the increasing number of dental clinics especially in emerging markets, rapid adoption of advanced technologies in these settings, and growth in the target patient population.

Europe dominated the market in 2016

Europe accounted for the largest share of the endodontics market in 2016, followed by North America. The large share of this region is attributed to the increasing prevalence of dental diseases, growth in the aging population, increasing demand for advanced dental procedures, growing dental tourism in some European countries, increasing number of dental clinics and hospitals, and increasing dental care expenditure in countries such as Germany and the UK.

The prominent players in the endodontics market are DENTSPLY SIRONA (US), Danaher Corporation (US), Ivoclar Vivadent (Liechtenstein), Ultradent Products (US), Septodont Holding (France), FKG Dentaire (Switzerland), Brasseler USA (US), MICRO-MEGA (France), DiaDent Group International (Canada), MANI (Japan), COLTENE Holding (Switzerland), and VOCO (Germany).

Vaccine Adjuvants Market worth 769.4 Million USD by 2021

The report "Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021", report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the vaccine adjuvants market along with the estimates and forecasts of the revenue and market share analysis.

Browse 90 market data tables with 42 figures spread through 156 pages and in-depth TOC on "Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021" 
https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html
Early buyers will receive 10% customization on reports.

The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5% from 2016 to 2021. The major factors driving the growth of this market are high prevalence of infectious and zoonotic diseases, increasing focus on immunization programs by various government bodies, and growing focus on improved and long-lasting immunization against existing and emerging diseases.

The report segments this market into product type, route of administration, disease type, applications, and application categories. On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. Particulate adjuvants are expected to account for the largest share of the market. Adjuvant emulsions, on the other hand, are projected to grow at the highest CAGR from 2016 to 2021 due to factors such as the proven efficacy and relatively fewer safety issues involved in the use of adjuvant emulsions.

On the basis of route of administration, the vaccine adjuvants market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. The rapidly growing geriatric population and increasing need for development of better vaccines for improved immunization are the key factors propelling the growth of this market.

On the basis of disease type, the vaccine adjuvants market includes infectious diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. High incidences of diseases and research investments in life sciences are the major factors driving the growth of this market.

Based on applications, the global vaccine adjuvants market is segmented into research and commercial applications. Research applications are expected to account for the largest share of the market during the forecast period. Growth in this segment is driven by factors such as increasing need for better immunization for the increasing geriatric population and increasing government funding in research to meet the unmet needs for safe and effective vaccine adjuvants.

https://www.marketsandmarkets.com/pdfdownload.asp?id=152603894

On the basis of application categories, the vaccine adjuvants market is segmented into human and veterinary adjuvants. Adjuvants for humans are expected to account for the largest share of the global vaccine adjuvants market in 2016 and are expected to grow at a higher CAGR in the application category segment.

The key players in the vaccine adjuvants market include Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).

Vaccine Adjuvants Market worth 769.4 Million USD by 2021

The report "Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021", report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the vaccine adjuvants market along with the estimates and forecasts of the revenue and market share analysis.

Browse 90 market data tables with 42 figures spread through 156 pages and in-depth TOC on "Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021" 
https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html
Early buyers will receive 10% customization on reports.

The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5% from 2016 to 2021. The major factors driving the growth of this market are high prevalence of infectious and zoonotic diseases, increasing focus on immunization programs by various government bodies, and growing focus on improved and long-lasting immunization against existing and emerging diseases.

The report segments this market into product type, route of administration, disease type, applications, and application categories. On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. Particulate adjuvants are expected to account for the largest share of the market. Adjuvant emulsions, on the other hand, are projected to grow at the highest CAGR from 2016 to 2021 due to factors such as the proven efficacy and relatively fewer safety issues involved in the use of adjuvant emulsions.

On the basis of route of administration, the vaccine adjuvants market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. The rapidly growing geriatric population and increasing need for development of better vaccines for improved immunization are the key factors propelling the growth of this market.

On the basis of disease type, the vaccine adjuvants market includes infectious diseases, cancer, and other diseases. The infectious diseases segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. High incidences of diseases and research investments in life sciences are the major factors driving the growth of this market.

Based on applications, the global vaccine adjuvants market is segmented into research and commercial applications. Research applications are expected to account for the largest share of the market during the forecast period. Growth in this segment is driven by factors such as increasing need for better immunization for the increasing geriatric population and increasing government funding in research to meet the unmet needs for safe and effective vaccine adjuvants.

https://www.marketsandmarkets.com/pdfdownload.asp?id=152603894

On the basis of application categories, the vaccine adjuvants market is segmented into human and veterinary adjuvants. Adjuvants for humans are expected to account for the largest share of the global vaccine adjuvants market in 2016 and are expected to grow at a higher CAGR in the application category segment.

The key players in the vaccine adjuvants market include Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).